{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. While the rating change occurred then, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Bliss GVS Pharma Ltd is Rated Hold by MarketsMOJO
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 12 Nov 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the company’s current position as of 07 March 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 12 Nov 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Bliss GVS Pharma Gains 2.50%: Key Price Milestones and Market Momentum in February
Bliss GVS Pharma Ltd recorded a 2.50% gain over the week ending 20 Feb 2026, outperforming the Sensex’s modest 0.39% rise. The stock’s momentum was propelled by significant milestones on 17 Feb, including a new 52-week high of Rs.244.05 and an all-time high closing price of Rs.228.35. Despite some profit-taking in the latter part of the week, the company demonstrated resilience amid mixed market conditions.
Bliss GVS Pharma Ltd Hits New 52-Week High at Rs.244.05
Bliss GVS Pharma Ltd has surged to a fresh 52-week high of Rs.244.05, marking a significant milestone in its stock performance. This new peak reflects robust momentum driven by sustained gains and strong market positioning within the Pharmaceuticals & Biotechnology sector.
Bliss GVS Pharma Ltd Stock Hits All-Time High at Rs.228.35
Bliss GVS Pharma Ltd has reached a new all-time high of Rs.228.35, underscoring a remarkable phase of growth and robust market performance within the Pharmaceuticals & Biotechnology sector. This milestone reflects the company’s sustained upward trajectory amid a challenging market environment.
Bliss GVS Pharma Gains 18.69%: 5 Key Factors Driving the Surge
Bliss GVS Pharma Ltd delivered a strong weekly performance, surging 18.69% from Rs.183.50 to Rs.217.80 between 09 and 13 February 2026, significantly outperforming the Sensex which declined 0.54% over the same period. The stock hit multiple new 52-week highs during the week, reflecting robust momentum amid mixed market conditions and a cautious broader environment.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 12 Nov 2025. While this rating change occurred several months ago, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 13 February 2026, providing investors with an up-to-date perspective on the company’s position in the market.
Bliss GVS Pharma Ltd Hits New 52-Week High of Rs.217.1
Bliss GVS Pharma Ltd has surged to a fresh 52-week high of Rs.217.1, marking a significant milestone in its stock performance. This new peak reflects robust momentum as the pharmaceutical company continues to outperform its sector and broader market indices.
Has Bliss GVS Pharma Ltd declared dividend?
Yes, Bliss GVS Pharma Ltd has declared a dividend of 50% (0.5 per share) with an ex-date of February 18, 2026. The company has shown strong total returns across various periods, indicating a positive financial performance.
Are Bliss GVS Pharma Ltd latest results good or bad?
Bliss GVS Pharma Ltd's latest Q3 FY26 results show mixed performance, with a 10.70% sequential decline in net sales and a 14.61% drop in net profit, raising concerns about earnings sustainability despite a strong balance sheet and cash generation capabilities. Investors should be cautious due to operational challenges and reliance on non-operating income.
Bliss GVS Pharma Ltd Hits New 52-Week High at Rs.216.6
Bliss GVS Pharma Ltd has surged to a fresh 52-week high of Rs.216.6, marking a significant milestone in its stock performance. This new peak reflects strong momentum as the pharmaceutical company outperformed its sector and sustained gains over recent sessions.
Bliss GVS Pharma Q3 FY26: Profit Decline Amid Volatile Other Income Clouds Performance
Bliss GVS Pharma Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹2,186 crores, reported a challenging third quarter for FY2026, with consolidated net profit declining 14.61% quarter-on-quarter to ₹23.27 crores despite a 3.72% year-on-year revenue growth. The stock, trading at ₹207.40, has surged 40.56% over the past year but faces questions about earnings quality as other income volatility masks underlying operational performance.
Bliss GVS Pharma Ltd Hits New 52-Week High of Rs.211.8
Bliss GVS Pharma Ltd has reached a significant milestone by hitting a new 52-week high of Rs.211.8, marking a notable surge in its stock price and reflecting strong momentum within the Pharmaceuticals & Biotechnology sector.
Bliss GVS Pharma Ltd Hits New 52-Week High of Rs 200
Bliss GVS Pharma Ltd has surged to a fresh 52-week high, touching Rs.200 today, reflecting robust momentum in the Pharmaceuticals & Biotechnology sector. This milestone underscores the stock’s strong performance over the past year, significantly outpacing broader market indices and sector peers.
When is the next results date for Bliss GVS Pharma Ltd?
The next results date for Bliss GVS Pharma Ltd is 10 February 2026.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into its performance and outlook.
Bliss GVS Pharma Ltd Hits Intraday High with 7.54% Surge on 29 Jan 2026
Bliss GVS Pharma Ltd demonstrated robust intraday performance on 29 Jan 2026, surging to an intraday high of Rs 178.65, marking a 7.54% increase from the previous close. The stock outperformed its sector and broader market indices, continuing its upward momentum amid positive trading activity.
Bliss GVS Pharma Ltd Falls 5.93%: 2 Key Factors Driving the Weekly Decline
Bliss GVS Pharma Ltd experienced a turbulent week ending 23 January 2026, with its share price declining 5.93% from Rs.172.15 to Rs.161.95, underperforming the Sensex which fell 3.31% over the same period. The stock showed early weakness with consecutive daily losses before staging a strong recovery on the final trading day, reflecting a complex interplay of technical signals and market sentiment.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
